New Delhi, January 12, 2026 – Rodec Pharma Limited has filed its Draft Red Herring Prospectus for an initial public offering, marking its entry into the primary market through a 100 percent book-built issue. The proposed public issue is entirely an offer for sale of up to 56.50 lakh equity shares with a face value of ₹10 each, to be divested by promoter and managing director Mukesh Kumar Gupta.
The equity shares are proposed to be listed on the BSE and NSE, with the designated exchange to be finalised closer to the offer opening. The company has already received in-principle approvals for listing on both exchanges.
IPO Structure and Offer Details
The IPO does not include a fresh issue component. As a result, Rodec Pharma will not receive any proceeds from the public issue. The entire offer proceeds, net of expenses and applicable taxes, will accrue to the promoter selling shareholder.The offer will be undertaken through the book-building route, with allocations proposed across qualified institutional buyers, non-institutional investors, and retail individual investors. A portion of the institutional book may be reserved for anchor investors. The price band and bid dates will be announced at a later stage.
As on the date of the DRHP, the company has 2.26 crore equity shares outstanding. Post-issue, the promoter shareholding will reduce in line with the offer-for-sale size, subject to final allotment.
Objects of the Issue
The primary objectives of the IPO are to facilitate the offer for sale by the promoter and to achieve the benefits of listing the company’s equity shares on the stock exchanges. These include enhanced corporate visibility, improved liquidity for shareholders, and access to the public equity markets for future capital requirements.Business Overview
Incorporated in 1997 and converted into a public limited company in 2024, Rodec Pharma operates in the animal healthcare segment. The company is engaged in the manufacturing of animal feed supplements and the marketing of veterinary pharmaceutical products catering to the nutritional and healthcare needs of livestock.Rodec Pharma commenced in-house manufacturing operations in December 2022. This transition has enabled tighter control over production, improved cost efficiency, and better alignment of output with market demand. The company’s manufacturing facility is compliant with international quality standards and holds FAMI-QS and ISO certifications.
Financial Performance
For the six months ended September 30, 2025, Rodec Pharma reported revenue from operations of ₹627.27 million and a profit after tax of ₹97.31 million. For FY25, the company recorded revenue of ₹1,063.93 million and profit after tax of ₹182.57 million, reflecting steady growth over the past three financial years.Net worth stood at ₹599.59 million as of September 30, 2025, while net debt turned negative, indicating a net cash position. Earnings per share for FY25 were reported at ₹8.08 on a face value of ₹10.
Promoters and Management
The company is promoted by Mukesh Kumar Gupta, Chhaya Gupta, and Utkarsh Gupta. Mukesh Kumar Gupta serves as Managing Director, while Chhaya Gupta is the Whole-Time Director. The promoters collectively held over 92 percent of the equity share capital prior to the offer.The promoter selling shareholder has confirmed that the shares offered have been held for more than one year prior to filing the DRHP.
About the Company
Rodec Pharma Limited is an animal healthcare company focused on manufacturing animal feed supplements and marketing veterinary pharmaceutical products. Headquartered in Ghaziabad, Uttar Pradesh, the company caters to livestock-focused markets across India and operates an in-house manufacturing facility aligned with international quality standards.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.